Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012 May; 66(5):742-51.

View in: PubMed

subject areas

Adult
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Drug-Related Side Effects and Adverse Reactions
Female
Follow-Up Studies
Humans
Long-Term Care
Male
Middle Aged
Neoplasms
Psoriasis
Risk Assessment
Safety Management
Severity of Illness Index
Time Factors
Treatment Outcome
Ustekinumab

authors with profiles

Kenneth Gordon